Evidence map›Paper›PMID 34307147›Full record

ArticleFrontiers in oncology2021

The Enhanced Inhibitory Effect of Estrogen on PD-L1 Expression Following Nrf2 Deficiency in the AOM/DSS Model of Colitis-Associated Cancer.

Changhee Kang, Chin-Hee Song, Nayoung Kim, Ryoung Hee Nam, Soo In Choi, Jeong Eun Yu, Heewon Nho, Jin A Choi, Jin Won Kim, Hee Young Na and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. 17β-estradiol in colorectal cancer: friend or foe?Cell communication and signaling : CCS · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Changhee KangDepartments of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Chin-Hee SongDepartments of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Nayoung KimDepartments of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Ryoung Hee NamDepartments of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Soo In ChoiDepartments of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Jeong Eun YuDepartments of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Heewon NhoDepartments of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Jin A ChoiDepartments of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Jin Won KimDepartments of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Hee Young NaDepartments of Pathology, Seoul National University Bundang Hospital, Seongnam, South Korea.
Ha-Na LeeLaboratory of Immunology, Division of Biotechnology Review and Research-III, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Young-Joon SurhDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea.
Seoul National University Bundang Hospital · KRCenter for Drug Evaluation and Research · USSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear factor erythroid 2-related factor 2 (Nrf2) plays a dual role in carcinogenesis. We previously reported that Nrf2 deficiency enhances the anti-tumorigenic effect of 17β-estradiol (E2) in an azoxymethane (AOM)/dextran sodium sulfate (DSS) model of colitis-associated cancer (CAC). Herein, we aimed to determine a possible explanation for our recent work and investigated the immune microenvironment represented by programmed death-ligand 1 (PD-L1) expression. One week after the AOM injection, mice were administered with DSS in drinking water for seven days; daily E2 injections were intraperitoneally administered during this period. The mice were sacrificed 16 weeks after AOM injection and analyzed for PD-L1 expression in the distal colon tissues using Western blotting and immunohistochemistry (IHC). Based on Western blotting results, PD-L1 expression was reduced in Nrf2 knockout (KO) female and E2-treated male mice when compared with their wild-type counterparts, following AOM/DSS treatment; this supports the association of PD-L1 expression with tumor progression. Additionally, this finding was in good agreement with the IHC results for PD-L1. Furthermore, we observed that PD-L1 is predominantly expressed in stromal cells rather than on epithelial cells in the colon. Western blotting revealed that PD-L1 expression in the colon positively correlates with expressions of inducible nitric oxide synthase (iNOS) (male,

Indexed as

17β-estradiolimmune microenvironmentinflammationNrf2programmed death-ligand 1

Identifiers

PMID34307147
PMCPMC8297827
OpenAlexW3181421871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.